Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Seeks Oncology Pipeline Boost Through Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Merger with Conforma Therapeutics, valued at up to $250 mil., brings Biogen Idec a stable of developmental heat shock protein inhibitors.

You may also be interested in...



Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition

Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.

Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition

Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.

MedImmune Bolsters Oncology Pipeline Under Agreement With Infinity

Deal for development of two candidates could be worth up to half a billion dollars.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel